High resolution melting for mutation scanning of TP53 exons 5–8

Michael Krypuy¹ , Ahmed Ashour Ahmed² , Dariush Etemadmoghadam³^,4 , Sarah J Hyland⁵ , Australian Ovarian Cancer Study Group , Anna deFazio⁶ , Stephen B Fox¹^,7 , James D Brenton² , David D Bowtell³^,4 and Alexander Dobrovic¹^,7

¹Molecular Pathology Research and Development Laboratory, Department of Pathology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Melbourne, Victoria 8006, Australia

²Functional Genomics of Drug Resistance Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way Cambridge CB2 0RE, UK

³Ian Potter Centre for Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Melbourne, Victoria 8006, Australia

⁴Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, 3010, Australia

⁵Hutchison/MRC Research Centre, University of Cambridge, Cambridge CB2 2XZ, UK

⁶Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, New South Wales 2145 Australia

⁷Department of Pathology, University of Melbourne, Parkville, Victoria, 3010, Australia

author email corresponding author email

BMC Cancer 2007, 7:168doi:10.1186/1471-2407-7-168


Published:	31 August 2007

Additional files

Additional file 1:

Difference plot of additional T47D dilutions. T47D was diluted at 95%, 90%, 75% and 1% (green) alongside original dilutions (orange). Wild type profiles are in blue. At dilutions of 95%, 90% and 75% the heteroduplex effect from the addition of wild-type DNA to T47D can be seen in altered shape of the melt profile.

Format: PNG Size: 207KB Download file